(Q39542019)

English

Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination

scientific article published on April 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Expression and purification of a natural N-terminal pre-ligand assembly domain of tumor necrosis factor receptor 1 (TNFR1 PLAD) and preliminary activity determination (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

author name string

Jin Cao

1

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Fang Meng

2

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Xiangdong Gao

3

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Hongxia Dong

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Wenbing Yao

5

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

publication date

1 April 2011

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

The Protein Journal

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

30

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

281-289

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

TNF-mediated inflammatory disease.

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Targeting TNF-alpha receptors for neurotherapeutics

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

The pre-ligand binding assembly domain: a potential target of inhibition of tumour necrosis factor receptor function

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

A domain in TNF receptors that mediates ligand-independent receptor assembly and signaling

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Signaling by the TNF receptor superfamily and T cell homeostasis

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

TNF-R1 signaling: a beautiful pathway

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Tumor necrosis factor receptor pre-ligand assembly domain is an important therapeutic target in inflammatory arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Amelioration of inflammatory arthritis by targeting the pre-ligand assembly domain of tumor necrosis factor receptors

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Lasker Clinical Medical Research Award. TNF defined as a therapeutic target for rheumatoid arthritis and other autoimmune diseases

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

New concepts in the treatment of rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Developing therapeutic proteins by engineering ligand-receptor interactions

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

TNF receptor subtype signalling: differences and cellular consequences

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Enhanced tumour necrosis factor and interleukin-1 in fulminant hepatic failure

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Hepatitis B and C virus infections and anti-tumor necrosis factor-alpha therapy: guidelines for clinical approach

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Monoclonal antibodies specific for murine p55 and p75 tumor necrosis factor receptors: identification of a novel in vivo role for p75

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Creation and X-ray structure analysis of the tumor necrosis factor receptor-1-selective mutant of a tumor necrosis factor-alpha antagonist

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

The therapeutic effect of TNFR1-selective antagonistic mutant TNF-alpha in murine hepatitis models

1 reference

https://api.crossref.org/works/10.1007%2FS10930-011-9330-4

21 January 2018

Development of anti-TNF therapy for rheumatoid arthritis

1 reference

https://pubmed.ncbi.nlm.nih.gov/21574063

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Drug-induced systemic lupus erythematosus associated with etanercept therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/21574063

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

The treatment of established murine collagen-induced arthritis with a TNFR1-selective antagonistic mutant TNF

1 reference

https://pubmed.ncbi.nlm.nih.gov/21574063

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration

1 reference

https://pubmed.ncbi.nlm.nih.gov/21574063

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Infliximab neutralizes the suppressive effect of TNF-alpha on expression of extracellular-superoxide dismutase in vitro

1 reference

https://pubmed.ncbi.nlm.nih.gov/21574063

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1007/S10930-011-9330-4

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39542019&oldid=2202965267"